When researching hyaluronic acid (HA) dermal fillers, prospective patients and aesthetic injectors frequently ask a deceptively simple question: "How long does Belotero last?"

Med spa consultations and consumer health portals routinely offer a single, broad duration range—claiming that "Belotero lasts 6 to 18 months depending on the formula." Consumer wellness sites like Healthline present tables listing Belotero Soft, Belotero Intense, and Belotero Volume alongside Belotero Balance, suggesting a spectrum of longevity from 6 to 18 months. Manufacturer promotional copy on belotero.com prominently advertises that results last "up to 18 months." Meanwhile, social media injectors debate whether Belotero in the lips disappears in 4 months or persists for a year.

The clinical and regulatory reality established by FDA Premarket Approval (PMA) records is that there is no single "Belotero duration." In the United States, commercially available Belotero gels sit across three distinct PMA numbers (all Class III medical devices under Product Code LMH, held by applicant Merz North America, Inc.):

P090016 (original approval November 14, 2011) for Belotero Balance in moderate-to-severe nasolabial folds (NLFs), expanded via supplement S050 on September 27, 2023 for infraorbital hollows;
P250020 (approved May 19, 2026) for Belotero Volume (+) Lidocaine in midface cheek augmentation; and
P250016 (approved July 9, 2026) for Belotero Intense (+) Lidocaine in lip augmentation.

Clinical persistence is strictly product- and anatomical-area-specific. Furthermore, manufacturer "up to" claims represent upper-bound responder ceilings following initial treatment plus an optional touch-up (optimal correction), not medians for a single, unretreated syringe.

A syringe of Belotero Balance placed superficially in delicate tear-trough hollows behaves completely differently from Belotero Volume placed supraperiosteally on the malar bone, Belotero Intense injected into the dynamic vermillion border of the lips, or original Balance in mid-dermal smile lines. For corporate PMA census data and adverse-event reporting, see our Merz Aesthetics portfolio analysis. For family shopping rather than duration tables, see Juvéderm vs. Restylane and RHA vs. Juvéderm. For cross-brand longevity comparisons, see how long Juvéderm lasts, how long Restylane lasts, how long RHA lasts, how long Radiesse lasts, and our comprehensive lip filler duration guide.

This guide analyzes official FDA Summary of Safety and Effectiveness Data (SSED) documents to map the exact clinical persistence, trial endpoints, responder rates, and limitations of each formulation in the US Belotero family.

                    [US Belotero Regulatory & Persistence Map]

  Product / Indication          PMA & Decision Date    Trial Efficacy Follow-Up & Responders          Labeled Ceiling
  ──────────────────────────    ───────────────────    ────────────────────────────────────────────   ────────────────────
  Belotero Balance              P090016 ORIG (2011)    W12 SRS: 1.25 vs bovine collagen 1.51 (n=118)   Up to 18 months*
  (Nasolabial Folds, Dermis)    Decision: 2011-11-14   W24 SRS >1-pt: 55.1%; OLEX retreatment 37 wks
  Belotero Balance (+)          P090016/S050 (2023)    W8 MIHAS: 85.4% (111/130); W12: 93.0% (120/129) Up to 48 weeks
  (Infraorbital Hollows)        Decision: 2023-09-27   W48 MIHAS: 81.4% (96/118); 55.6% touch-up
  Belotero Volume (+) Lidocaine P250020 (2026)         W12 MCFAS Live: 95.8% (137/143) vs Lyft 95.7%  Up to 48 weeks
  (Cheek / Midface Augmentation)Decision: 2026-05-19   W12 IPR Photo: 46.2% (66/143); 60% touch-up    (Majority, 74%)**
  Belotero Intense (+) LidocaineP250016 (2026)         W8 MLFAS Live: 91.1% (144/158) vs control 90.4% Up to 48 weeks
  (Lip Augmentation, Adults 21+)Decision: 2026-07-09   W48 MLFAS Live: 48.7% (73/150); W48 GAIS: 92%  (Repeat to 60 wks)

*The 18-month Balance HCP envelope footnotes 20/22 Week-8 responders still responding at 72 weeks. That n/N is the P090016/S050 infraorbital subset who did not receive retreatment (90.9%), not the original NLF 12-week primary. **Patient labeling P250020C confirms cheek results lasted up to 48 weeks in 74% of subjects and up to 72 weeks in some responders; the Volume SSED prints no tabulated Week-48 MCFAS n/N.

Direct Answer: Does Belotero Really Last 6 to 18 Months?

When evaluating Belotero longevity claims, clinicians and patients must distinguish FDA trial endpoints from marketing summaries:

No Single Duration Exists: There is no universal "Belotero duration." In the US, the brand encompasses three distinct PMAs: original Balance (folds and under-eyes), Volume (cheeks), and Intense (lips). Each formula possesses distinct hyaluronic acid concentrations, degree of cross-linking, and clinical trial persistence curves.
Healthline's 6-to-18-Month Range Mixes European SKUs: The popular online claim that Belotero lasts 6 to 18 months across "Soft, Intense, Volume, and Balance" is based on European CE-mark marketing. In Europe, Belotero Soft and Revive are sold for superficial hydration, while European Intense is marketed for severe nasolabial folds and oral commissures. In the US, Belotero Soft and Revive are not FDA-approved, and Belotero Intense was approved on July 9, 2026 exclusively for lip augmentation.
What "Up to 18 Months" Actually Means: Manufacturer marketing for Belotero Balance cites persistence "up to 18 months." The US HCP site footnotes that claim with 20 of 22 Week-8 responders (90.9%) still responding at 72 weeks. That fraction is the P090016/S050 infraorbital no-retreatment subset, not the original NLF 12-week primary. It is not an intention-to-treat median. The original NLF primary endpoint was Week 12 mean SRS versus bovine collagen.
Cheek Volume Lasts Up to 48 Weeks, Not Voluma's 24 Months: Belotero Volume (+) Lidocaine was approved under P250020 on May 19, 2026. The US HCP site also prints "lasts up to 18 months" on Volume. Official US patient labeling states that cheek volume lasted up to 48 weeks in the majority (74%) of participants, with some maintaining results up to 72 weeks. It does not possess the 24-month FDA-approved persistence table of Juvéderm Voluma XC.
Lip Intense Shows ~49% Fullness at 1 Year Despite High Satisfaction Scores: In the pivotal lip trial for Belotero Intense (P250016), live blinded evaluators judged that 91.1% (144/158) of subjects achieved ≥1-point fullness improvement at Week 8. By Week 48, objective lip fullness dropped to 48.7% (73/150). Week-48 GAIS (improved, much improved, or very much improved) remained 92.0% (138/150) by investigator and 90.0% (135/150) by subject — a different instrument from MLFAS fullness.
Under-Eye Balance (+) Demonstrates 81.4% Durability at 48 Weeks: In the pivotal infraorbital hollow trial (P090016/S050), 81.4% (96/118) of evaluable participants demonstrated continued bilateral improvement at Week 48. The widely quoted clinic statistic of "90.7% retention" refers specifically to the subset of Week-8 initial responders who remained responders at Week 48 (88/97), not 90.7% of all treated subjects.
The "Optimal Correction" Prerequisite: All published duration metrics in FDA SSEDs reflect protocols where subjects received initial baseline injection plus an optional touch-up session (79.7% for NLF Balance, 55.6% for infraorbital Balance, 60% for Volume cheeks, and 70.9% for Intense lips). An under-corrected treatment using half a syringe split across multiple facial zones will not match these published durability rates.
Skip an Unspecified Quote: If a provider quotes a price for "Belotero" without identifying whether the syringe is Balance, Volume, or Intense, or if a clinic advertises European "Belotero Soft" skin boosters in the US, decline treatment until the exact FDA-approved product and indication are verified.

The Regulatory Architecture: Three US PMAs and Cohesive Polydensified Matrix (CPM) Technology

In the FDA CDRH Premarket Approval database (Class III medical devices, Product Code LMH), the US Belotero portfolio is held by Merz North America, Inc. A comprehensive audit of the FDA PMA database (as of the August 2026 data snapshot containing 56,765 total PMA records) demonstrates that Merz operates three distinct PMA lines for Belotero:

                    [Merz US Belotero PMA Architecture]

  PMA Number    Supplement    Decision Date   Branded Trade Name               Approved US Indication
  ──────────    ──────────    ─────────────   ──────────────────────────────   ──────────────────────────────────────────────────────────
  P090016       ORIG          2011-11-14      BELOTERO BALANCE                 Moderate-to-severe facial wrinkles & folds (NLFs)
  P090016       S028          2019-08-29      Belotero Balance (+) Lidocaine   Integral lidocaine (identity; not a duration table)
  P090016       S050          2023-09-27      Belotero Balance (+) Lidocaine   Infraorbital hollows (tear troughs) in adults >21
  P250020       ORIG          2026-05-19      Belotero Volume (+) Lidocaine    Midface cheek augmentation (deep subQ / supraperiosteal)
  P250016       ORIG          2026-07-09      Belotero Intense (+) Lidocaine   Lip augmentation (submucosal / subcutaneous) in adults >21

Source: FDA CDRH Premarket Approval Database, Product Code LMH, applicant Merz North America, Inc. Across all 56,765 PMA database rows, exactly zero trade-name entries match Belotero Soft, Belotero Revive, or Belotero Lips.

Unlike Allergan (which consolidated its Juvéderm portfolio into Hylacross P050047 and Vycross P110033) or Teoxane (which expanded its RHA line entirely under P170002), Merz introduced original Belotero Balance under P090016, and then filed separate original PMAs for Belotero Volume (P250020) and Belotero Intense (P250016) in 2026.

Cohesive Polydensified Matrix (CPM) Technology

All Belotero formulations are manufactured using Merz's proprietary Cohesive Polydensified Matrix (CPM) process. Traditional biphasic HA fillers (such as original Restylane NASHA) use chemical cross-linking followed by mechanical sizing to create uniform gel particles suspended in a fluid carrier. Monophasic monodensified fillers (such as Juvéderm Hylacross) create a homogenous cross-linked gel network.

In contrast, the patented CPM process employs a two-step cross-linking dynamic:

Hyaluronic acid chains are cross-linked with 1,4-butanediol diglycidyl ether (BDDE) to form a standard monophasic gel.
The gel is stretched, unraveled, and combined with additional native HA and BDDE for a second cross-linking stage.

This produces a polydensified gel containing micro-zones of high density (high cross-linking) interwoven with zones of low density (low cross-linking).

                       [CPM Microstructural Density Concept]

    Traditional Monophasic Gel                  Cohesive Polydensified Matrix (CPM)
   ┌──────────────────────────────┐            ┌──────────────────────────────┐
   │  ██████████████████████████  │            │  ████  ░░░░  ██████  ░░░░░░  │  (High-density zones
   │  ██████████████████████████  │            │  ░░░░  ████  ░░░░░░  ██████  │   provide structural
   │  ██████████████████████████  │     vs     │  ██████  ░░  ██████  ░░░░    │   projection; low-density
   │  ██████████████████████████  │            │  ░░░░░░  ██  ░░░░░░  ██████  │   zones facilitate tissue
   │  ██████████████████████████  │            │  ████  ░░░░  ██████  ░░░░░░  │   integration)
   └──────────────────────────────┘            └──────────────────────────────┘
      Uniform High Elasticity                     Variable Density / Seamless Integration

Clinical Consequences of CPM Rheology

Seamless Tissue Integration: The low-density zones allow the gel to flow into microscopic interstitial spaces in the dermis, integrating smoothly into surrounding collagen fibers rather than forming a distinct bolus.
Lower Tyndall reporting in the hollows trial: When conventional HA gels are injected superficially into the thin skin of the lower eyelid, light scattering through the gel can produce a bluish discoloration known as the Tyndall effect. The P090016/S050 infraorbital study reported no Tyndall effect. That is a trial-safety finding, not a guarantee that superficial HA can never Tyndall; technique, depth, and volume still matter.
Metabolic Tradeoff: Because the low-density zones integrate so intimately with host tissue, they are more exposed to endogenous tissue hyaluronidases and mechanical shear stress. Consequently, in high-mobility dynamic zones (such as the perioral complex), unretreated Belotero can undergo faster initial resorption than dense, highly cross-linked monolithic gels.

Is There One Belotero Duration, or Does Each US PMA and Area Have Its Own Table?

There is no universal Belotero duration figure. Longevity is governed by three variables: gel concentration and cross-linking, injection depth (superficial dermis vs. deep subcutaneous / supraperiosteal bone), and local mechanical movement (static infraorbital hollows vs. mobile lips).

Below is the detailed product-by-product breakdown from official FDA SSED trial tables.

1. Belotero Balance in Nasolabial Folds (P090016 ORIG, November 14, 2011)

Indication: Mid-to-deep dermis injection for the correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds, in adult patients.
Formulation: 22.5 mg/mL cross-linked sodium hyaluronate in phosphate-buffered saline (without lidocaine in the original approval; integral 0.3% lidocaine added via S028 in 2019).
Pivotal Trial Architecture (MUS 90028-00622-1): Prospective, multicenter, randomized, blinded, split-face clinical study (n=118) comparing Belotero Balance against an active control: bovine collagen. (Consumer blogs and even commercial portfolios frequently mislabel the control as Restylane; the FDA SSED identifies the randomized comparator only as an FDA-approved bovine collagen dermal filler, not Restylane.)
Touch-Up Protocol: At Week 2, an optional touch-up was performed if optimal correction was not achieved. 79.7% of subjects (94/118) received a touch-up injection.
Primary Effectiveness Endpoint (Week 12): Mean Blinded Evaluator Severity Rating Scale (SRS, 0–4 scale) at Week 12:
- Baseline SRS: 2.5 on both Belotero and collagen sides.
- Week 12 Belotero SRS: 1.25 (mean improvement of 1.25 points).
- Week 12 Collagen SRS: 1.51 (mean improvement of 0.99 points).
- The SSED conclusions state non-inferiority to collagen. The protocol also defined a superiority test (lower 95% CI bound of the SRS difference > 0). Table 7 prints the means; it does not print a p-value, and the effectiveness conclusions do not claim superiority.

                 [NLF Pivotal Trial SRS Severity at Week 12 (n=118)]

  Treatment Arm        Baseline Mean SRS    Week 12 Mean SRS    Mean SRS Reduction
  ─────────────────    ─────────────────    ────────────────    ──────────────────
  Belotero Balance     2.50                 1.25                -1.25 (non-inferior per SSED)
  Bovine Collagen      2.50                 1.51                -0.99

The 24-Week and 18-Month Persistence Reality in Folds

Week 24 Blinded Assessment: At Week 24 (6 months post-treatment), masked evaluators judged that 55.1% of Belotero-treated nasolabial folds maintained greater than a 1-point SRS improvement from baseline.
The 89% Completion vs. Responder Error: Clinic marketing materials often state that "89% of patients maintained correction at 6 months." This is a statistical conflation. FDA SSED Table 3 confirms that 89.8% (106/118) completed the 24-week evaluation visit; actual blinded responder rates were 55.1%.
Open-Label Extension (OLEX, Weeks 24–96): Subjects who completed Week 24 were eligible for an open-label extension lasting up to 96 weeks. If an NLF returned to an SRS score of 2 or 3, retreatment was offered. A total of 95 of the 106 subjects (89.6%) elected to receive retreatment during OLEX. The SSED reports a mean time between injections of 37 weeks on the originally Belotero-treated side during the extension (31 weeks on the originally collagen-treated side). That is an inter-injection interval after Week 24, not the time from the first syringe to first retreatment.
Original IFU Restrictions: The FDA-approved Instructions for Use (P090016C) state:
- Injection into the lips has not been evaluated under P090016.
- Total injection volume should not exceed 6.0 mL per patient per year.
- Long-term safety beyond 96 weeks has not been investigated.
Fitzpatrick Skin Types IV–VI: A dedicated NLF study enrolled 93 subjects with Fitzpatrick Skin Types IV–VI; 88 of 93 completed, and 70.1% (66/93) received a Week-2 touch-up. The SSED states that the safety profile was similar to the pivotal study. History of keloids was an exclusion criterion in the pivotal trial; do not read that as a published "no keloids / no PIH" rate.

2. Belotero Balance (+) in Infraorbital Hollows (P090016/S050, September 27, 2023)

On September 27, 2023, the FDA approved P090016/S050, making Belotero Balance (+) Lidocaine the third US on-label infraorbital hyaluronic acid filler after Juvéderm Volbella XC (P110033/S053) and Restylane Eyelight (Restylane-L infraorbital indication), and before RHA Redensity Eye (P170002/S050, May 12, 2026).

Indication: Volume augmentation of the infraorbital hollow in adult patients over the age of 21.
Pivotal Trial Architecture (Study M930121002): Prospective, randomized, delayed-treatment-controlled, evaluator-blinded study. 150 subjects were randomized 2:1 (97 immediate treatment vs. 53 delayed-treatment control). The safety population comprised 144 treated subjects.
Touch-Up Rate: An optional touch-up was offered at Week 4. 55.6% of subjects (80/144) received a touch-up session.
Primary Effectiveness Endpoint (Week 8): ITT multiple-imputation MIHAS responder rate (both hollows ≥1-grade): 80.6% in the treatment group (n=97) versus 1.9% in the untreated control group (n=53). A responder was defined as ≥1-grade improvement on both infraorbital hollows on the 5-grade Merz Infraorbital Hollow Assessment Scale (MIHAS). Do not paste the pilot untreated rate 2/21 (9.5%) from M930121001 onto this pivotal Week-8 contrast.
Observed Durability Through Week 48 (Table 23, all treated, observed cases; Weeks 8–48 are post last injection):
- Week 8: 85.4% (111/130) bilateral responders.
- Week 12: 93.0% (120/129) bilateral responders.
- Week 24: 84.4% (108/128) bilateral responders.
- Week 36: 82.9% (102/123) bilateral responders.
- Week 48: 81.4% (96/118) bilateral responders among evaluable participants.
FDA Recently-Approved Summary Language: Official FDA consumer documentation states that "results may last up to 48 weeks" following initial treatment and touch-up.

                 [Infraorbital Hollows MIHAS Bilateral Responders (P090016/S050)]

  Timepoint     Evaluable Subjects (N)    Observed Responders (n)    Bilateral Responder Rate (%)
  ──────────    ──────────────────────    ───────────────────────    ────────────────────────────
  Week 8        130                       111                        85.4%
  Week 12       129                       120                        93.0%
  Week 24       128                       108                        84.4%
  Week 36       123                       102                        82.9%
  Week 48       118                       96                         81.4%

Dissecting the Clinic "90.7% Retention" Statistic

Many med spa websites advertise that "over 90% of patients maintain tear trough correction at one year." The SSED benefit-risk paragraph is narrower:

88/97 (90.7%) is the share of Week-8 responders who still met responder criteria at Week 48, not 90.7% of the original 97-person treatment arm and not 90.7% of the 118 subjects observed at Week 48.
When examining all treated participants observed at Week 48 (Table 23), the bilateral responder rate was 81.4% (96/118).
In the subset who did not receive retreatment, 20/22 (90.9%) still responded at 72 weeks. That is the n/N the US HCP site footnotes for Balance "up to 18 months."
Following the Week-48 visit, optional repeat treatment was offered; 55 of 97 in the original treatment-arm randomization group elected retreatment. For alternative under-eye indications, see RHA Redensity Eye and our tear trough cost and risk guide.

3. Belotero Volume (+) Lidocaine in Cheeks and Midface (P250020, May 19, 2026)

On May 19, 2026, the FDA granted Premarket Approval to P250020 for Belotero Volume (+) Lidocaine, expanding the US portfolio into structural midface volumization.

Indication: Deep subcutaneous and/or supraperiosteal injection for cheek augmentation to correct age-related midface volume deficit in adults aged 22 and older.
Formulation: 26.0 mg/mL hyaluronic acid with lidocaine. That is the highest HA concentration among the three US Belotero PMAs (Balance 22.5 mg/mL; Intense 25.5 mg/mL). Cohesivity marketing is manufacturer rheology, not an SSED duration table.
Pivotal Clinical Trial (NCT04886232): Multicenter, randomized, active-controlled, evaluator-blinded trial conducted outside the United States (10 sites, all in Germany). 202 participants were randomized: 152 to Belotero Volume (+) and 50 to Restylane Lyft Lidocaine. One comparator participant discontinued before first treatment (safety set 152 vs 49). Assignment was 3:3:1:1 by needle/cannula laterality, not a simple 3:1 syringe split.
Touch-Up Rate: An optional touch-up was administered at Week 4; US patient labeling states that 60% of Belotero Volume participants received a touch-up.
Primary Effectiveness Endpoint (Week 12): Blinded Live Evaluator assessment of the 5-point Merz Cheek Fullness Assessment Scale (MCFAS). Success required demonstrating non-inferiority in mean change from baseline on the Per-Protocol Set (PPS):
- Mean MCFAS Change at Week 12: -1.60 points for Belotero Volume (n=143) vs. -1.55 points for Restylane Lyft (n=47).
- Live Both-Cheek Responder Rate (≥1-point improvement): 95.8% (137/143) for Belotero Volume vs. 95.7% (45/47) for Restylane Lyft.
- Marked Improvement (≥2-point improvement): 49.0% (71/145) in the Belotero Volume arm achieved at least a 2-point reduction in midface deficiency.

              [Cheek Augmentation Efficacy at Week 12: Belotero Volume vs. Lyft]

  Endpoint (Week 12)                Belotero Volume (+) (n=143)    Restylane Lyft Lidocaine (n=47)
  ──────────────────────────────    ───────────────────────────    ───────────────────────────────
  Mean MCFAS Change from Baseline   -1.60                          -1.55
  Live BLE Responder Rate (≥1-pt)   95.8% (137/143)                95.7% (45/47)
  Blinded Photo IPR Responder Rate  46.2% (66/143)                 34.0% (16/47)
  Marked Improvement (≥2-pt, ITTS)  49.0% (71/145)                 not tabulated beside 71/145

Does Labeled Cheek Volume Last 18 Months or Voluma's 24-Month Table, or 137/143 at Week 12 with a 48-Week IFU Ceiling?

Consumer med spa marketing frequently transfers longevity claims from other brands or European brochures:

The Live vs. Photographic Drop: While live evaluators scored 95.8% of Belotero Volume subjects as responders at Week 12, the independent photographic review panel (IPR, evaluating standardized 2D photographs) scored only 46.2% (66/143) as responders. This substantial divergence reflects the subtle nature of soft tissue projection and underscores why live clinical assessments report higher numbers than blinded photographic panels.
The 48-Week Patient Labeling Ceiling: Official US patient labeling (P250020C) states: "Cheek results lasted up to 48 weeks in the majority of participants (74%), and for some, up to 72 weeks." The SSED itself does not print a tabulated Week-48 MCFAS n/N fraction; the 74% majority rate is the verified labeling claim.
Volume is NOT Voluma's 24-Month Table: Juvéderm Voluma XC (P110033) holds an FDA-approved 24-month persistence table (67.1% of subjects maintaining correction at Month 24). Belotero Volume does not have a 24-month FDA data table; applying Voluma's two-year timeline to Belotero Volume is clinically inaccurate. For midface comparative shopping, see Restylane Lyft vs. Voluma and our 2025–2026 new dermal fillers guide.

4. Belotero Intense (+) Lidocaine in Lip Augmentation (P250016, July 9, 2026)

On July 9, 2026, the FDA approved P250016 for Belotero Intense (+) Lidocaine, introducing the first Belotero formulation officially labeled for lip augmentation in the United States.

Indication: Submucosal and/or subcutaneous injection for lip augmentation in patients over the age of 21.
Formulation: 25.5 mg/mL hyaluronic acid with 3.0 mg/mL lidocaine.
The European vs. US Identity Split: In Europe, Belotero Intense has long been marketed as a heavy, high-elasticity gel for severe nasolabial folds, deep oral commissures, and facial contours. In the US regulatory framework, P250016 is exclusively approved for the lips. Injectors familiar with European literature must not confuse European deep-fold protocols with the US lip indication.
Pivotal Clinical Trial (NCT05773066): Multicenter, randomized, active-controlled, evaluator-blinded study comparing Belotero Intense (n=165) against an unnamed legally marketed US FDA-approved lip filler comparator (n=55) in a 3:1 ratio.
Touch-Up Rate: An optional touch-up was performed at Week 4; 70.9% of subjects (117/165) received a touch-up injection.
Primary Effectiveness Endpoint (Week 8): Blinded Live Evaluator assessment of the 5-point Merz Lip Fullness Assessment Scale (MLFAS). Responders achieved ≥1-point improvement from baseline on the Per-Protocol Set:
- Week 8 MLFAS Live Responders: 91.1% (144/158) for Belotero Intense vs. 90.4% (47/52) for the active comparator.
- Week 8 Photographic IPR: 58.2% (92/158) for Belotero Intense vs. 59.6% (31/52) for comparator.

               [Lip Augmentation Durability Through Week 48 (P250016 Table 14)]

  Evaluation Timepoint    Belotero Intense Responders (n/N)    Active Lip Comparator (n/N)
  ────────────────────    ─────────────────────────────────    ───────────────────────────
  Week 8 (Primary BLE)    91.1% (144/158)                      90.4% (47/52)
  Week 8 (Blinded Photo)  58.2% (92/158)                       59.6% (31/52)
  Week 24 (6 Months)      78.8% (119/151)                      72.9% (35/48)
  Week 48 (12 Months)     48.7% (73/150)                       47.8% (22/46)

Objective Lip Fullness vs. Subjective Aesthetic Satisfaction

The SSED for Belotero Intense highlights a crucial dynamic in lip filler longevity:

The Objective Drop at 1 Year: On the validated MLFAS scale, objective lip fullness dropped from 91.1% at Week 8 to 78.8% at Week 24, and reached 48.7% (73/150) at Week 48. Fewer than half of participants maintained a full 1-grade lip volume increase at 12 months.
Subjective Satisfaction Persists: Despite the objective volume decrease, subject and investigator assessments on the Global Aesthetic Improvement Scale (GAIS) remained high at Week 48 for any improvement (improved, much improved, or very much improved):
- Investigator GAIS: 92.0% (138/150).
- Subject GAIS: 90.0% (135/150).
Clinical Meaning: While patients still feel their lips look better, softer, and smoother at one year, actual dimensional fullness has diminished by half. Claiming that "Belotero Intense lip filler lasts 12 months" is accurate for overall aesthetic satisfaction, but misleading if patients expect initial post-injection plumpness. Official patient labeling (P250016C) notes that benefits from a single treatment last up to 48 weeks, while repeat treatment extends satisfaction up to 60 weeks.

Is Healthline 6 to 18 Months a US Label Map, or EU Soft/Intense/Volume Mixing?

A prominent driver of consumer confusion is Healthline's widely circulated Belotero overview, which presents the following product lineup:

Belotero Soft: Fine lines, crow's feet, lasting up to 12 months.
Belotero Balance: Moderate lines and lip enhancement, lasting 6 months.
Belotero Intense: Deep lines and lip volume, lasting up to 12 months.
Belotero Volume: Cheeks and temples, lasting up to 18 months.

This table is not a US regulatory map. It reflects European CE-mark commercial positioning from the 2010s:

Belotero Soft is NOT FDA-Approved: A search of the FDA PMA database confirms zero rows for Belotero Soft. Any US clinic offering Belotero Soft is using an unapproved foreign product.
Original Belotero Balance was NOT Approved for Lips: The original P090016 IFU explicitly stated that lip injection had not been evaluated. While Balance was widely used off-label for lips before 2026, the on-label US lip indication belongs to Belotero Intense under P250016.
Belotero Intense is NOT a US Deep-Fold Gel: In Europe, Intense is positioned for severe folds; in the US, P250016 approved it specifically for lips.
Belotero Volume Cheeks Last 48 Weeks, Not 18 Months: As established in P250020C, US patient labeling sets a 48-week threshold for the majority of patients.

Is US Belotero Intense the EU Deep-Fold Gel, or P250016 Lips as of 9 July 2026?

Aesthetic providers reading international textbooks often encounter Belotero Intense described as a high-G-prime, high-viscosity gel intended for deep oral commissures, marionette lines, and deep nasolabial furrows.

In the United States, Belotero Intense (+) Lidocaine is an FDA-approved lip filler as of July 9, 2026 (P250016). Merz pursued lip augmentation for the US pivotal trial (NCT05773066). Injecting Belotero Intense into deep facial folds in the US is legally off-label, whereas injecting it into the submucosal lip body and vermillion border is on-label. Conversely, Belotero Balance is on-label for folds and infraorbital hollows, but not for lips.

Is Manufacturer Up to 18 Months a Median, or a Marketing Envelope That Does Not Match ORIG Week-12 SRS or Volume 74% at 48 Weeks?

Manufacturer marketing on belotero.com prominently states that Belotero results last "up to 18 months."

Patients must understand the regulatory origin of this claim:

In the original P090016 NLF filing, the primary blinded efficacy window was 12 weeks. At 24 weeks, 55.1% of folds showed continued >1-point improvement. 95/106 completers elected OLEX retreatment, and the mean interval between injections during OLEX was 37 weeks on the originally Belotero-treated side.
The HCP 18-month Balance figure footnotes 20/22 (90.9%) Week-8 responders still responding at 72 weeks — the S050 infraorbital no-retreatment subset, not the NLF primary table.
The same HCP homepage also prints "lasts up to 18 months" on Volume. US Volume patient labeling confirms that 74% maintain correction at 48 weeks, with only "some" extending to 72 weeks (about 18 months).
Conclusion: "Up to 18 months" is an upper-bound marketing envelope reflecting selected long-term responders, often after touch-up. It is not an intention-to-treat median. Realistic planning from these tables is retreatment in the 6-to-12-month window for Balance folds (55.1% still >1-point at Week 24; OLEX injections every ~37 weeks), about 48 weeks for a majority of Volume cheeks, and 6 to 9 months of labeled fullness for Intense lips (MLFAS 48.7% at Week 48).

Direct Comparison: Belotero vs. Juvéderm vs. Restylane vs. RHA

When selecting between the major US hyaluronic acid families, longevity must be weighed against rheology, tissue integration, and the risk of surface irregularities:

                          [Major US Hyaluronic Acid Filler Families]

  Attribute               Merz Belotero              Allergan Juvéderm          Galderma Restylane         Teoxane RHA
  ─────────────────────   ────────────────────────   ────────────────────────   ────────────────────────   ────────────────────────
  PMA Numbers             3 PMAs (P090016, P250020,  2 PMAs (P050047,           3 PMAs (P020023, P040024,  1 PMA (P170002)
                          P250016)                   P110033)                   P140029)
  Core Technology         Cohesive Polydensified     Hylacross & Vycross        NASHA & XpresHAn (OBT)     Preserved Network (PNT)
                          Matrix (CPM)
  Primary Clinical StrengthComplete tissue           Volumetric projection,     Firm structural lift       Dynamic tissue flexibility,
                          integration, no Tyndall    high water binding         (NASHA), natural flex (OBT)resilience to shear
  Nasolabial Fold Life    8–12 mos (W24: 55.1%)      Up to 12–18 mos (Vollure)  Up to 12–18 mos (Defyne)   Up to 15 mos (W64 GAI)
  Under-Eye Tear Troughs  Up to 48 wks (W48: 81.4%)  Up to 12 mos (Volbella)    Up to 12–18 mos (Eyelight) Up to 52 wks (Redensity Eye)
  Cheek Augmentation      Up to 48 wks (W48: 74%)    Up to 24 mos (Voluma)      Up to 12–18 mos (Lyft)     Up to 52 wks (Dynamic Vol)
  Lip Augmentation        6–12 mos (W48: 48.7%)      Up to 12 mos (Volbella)    Up to 12 mos (Kysse)       Up to 12 mos (RHA 3)
  Reversibility           Hyaluronidase soluble      Hyaluronidase soluble      Hyaluronidase soluble      Hyaluronidase soluble

Longevity vs. Integration: The Clinical Tradeoff

Why choose Belotero if Juvéderm Voluma lasts up to 24 months in the cheeks, or Restylane Defyne lasts up to 18 months in folds?

Lower Tyndall reporting in the S050 hollows trial: In the delicate infraorbital hollows, older gels can show bluish discoloration or visible fluid festoons. The Balance (+) hollows SSED reported no Tyndall effect in that study. That is not a "zero Tyndall" guarantee for every superficial HA injection.
Superficial Etching: For fine perioral "smoker's lines" and superficial etched facial wrinkles, high-G-prime fillers cause palpable bead-like nodules. Belotero Balance can be injected into the immediate superficial papillary dermis (the blanching technique) without creating bumps.
Dynamic lip feel is a shopping reason, not a duration number: Patients often choose a CPM lip gel because it feels less firm than a high-G-prime fold gel. That preference is not an SSED fullness table; Week-48 MLFAS was 48.7% (73/150).
Cost Context: Cash-pay syringe prices vary by SKU, market, and how many milliliters the quote actually includes. A number without Balance versus Volume versus Intense cannot be mapped to these tables. For syringe math and budgeting across filler brands, see our lip filler cost per syringe guide.

Safety, Complications, and Reversibility

Like all FDA-regulated Class III hyaluronic acid dermal fillers, Belotero carries specific safety considerations:

Hyaluronidase Reversibility: Because Belotero consists of cross-linked hyaluronic acid, it can be dissolved with injected hyaluronidase. This guide does not provide an emergency clinical treatment protocol; for reversal timing and what to ask, see dissolving filler with hyaluronidase.
Vascular Occlusion Risk: Unintentional intravascular injection into facial arteries (such as the angular, facial, or infraorbital arteries) can cause localized skin necrosis or, in rare cases, retrograde embolization leading to blindness. Every patient must review vascular risk symptoms (blanching, severe disproportionate pain, mottling) with their provider before treatment. See filler vascular occlusion diagnosis and management.
Fitzpatrick Skin Types IV–VI Safety: The original NLF FST IV–VI study (93 subjects) reported a safety profile similar to the pivotal trial. The Volume pivotal enrolled a minimum 20% FST IV–VI. Neither SSED publishes a "no keloids / no long-term PIH" rate as a standalone claim. Aggressive superficial needle passes can still induce mechanical melanocyte trauma; ask how the injector plans depth and instrument.
Contraindications: Belotero is strictly contraindicated in patients with severe allergies manifested by a history of anaphylaxis, allergies to gram-positive bacterial proteins (used in bacterial fermentation), and known hypersensitivity to lidocaine (for lidocaine-containing formulations).

Who Should Skip a Belotero Quote (Unnamed SKU, Soft/Revive, EU Intense as US Lips, Voluma 24-Month Applied to Volume, Balance as On-Label Lips, Pregnant/Breastfeeding)?

Patients should pause and reconsider treatment if they encounter any of the following red flags during a consultation:

The Unnamed SKU Quote: If a provider quotes a flat price for a "Belotero treatment" without specifying whether they will use Belotero Balance, Belotero Volume, or Belotero Intense, decline the quote. Each formulation has a distinct thickness, depth of placement, and longevity profile.
Promises of Belotero Soft or Belotero Revive: If an aesthetic med spa claims to offer "Belotero Soft skin boosters" or "Belotero Revive micro-injections" within the United States, recognize that these products have zero trade-name approvals in the FDA PMA database. That is an unapproved-device problem, not off-label use of Balance, Volume, or Intense.
Applying European Intense Indications to US Lips: If an injector recommends Belotero Intense for deep nasolabial folds based on European textbooks, recognize that P250016 approved Intense specifically for lip augmentation in the US.
Expecting 24-Month Duration from Belotero Volume: If an injector promises that Belotero Volume in your cheeks will last two years "just like Voluma," understand that regulatory patient labeling sets a 48-week expectation for the majority (74%) of patients.
Treating Belotero Balance as an On-Label Lip Filler: While Balance has historically been used off-label in the lips, original FDA labeling specifically notes that lips were not evaluated, and the formal US lip indication now belongs to Belotero Intense (P250016).
Expecting 18 Months from an Under-Corrected Syringe: SSED durability data required complete initial correction followed by an optional touch-up. Splitting a single 1.0 mL syringe across under-eyes, smile lines, and lips will not match those published responder rates.
Pregnancy or Breastfeeding: The safety of Belotero has not been established in pregnant or nursing women; elective cosmetic filler treatments should be deferred.

Frequently Asked Questions

How long does Belotero last compared to Juvéderm or Restylane?

In moderate facial folds and superficial lines, Belotero Balance's NLF table is a Week-12 SRS primary (mean 1.25 vs. collagen 1.51) with 55.1% still showing >1-point improvement at Week 24 and a 37-week mean injection interval during OLEX, in the same neighborhood as Restylane-L and Juvéderm Ultra rather than Voluma's 24-month cheek table. In the under-eye infraorbital hollows, Belotero Balance (+) demonstrates 81.4% (96/118) observed bilateral durability at 48 weeks. In structural cheek volumization, Juvéderm Voluma XC has an FDA-approved 24-month table, whereas Belotero Volume is labeled for up to 48 weeks in the majority of patients.

How long does Belotero Balance last in folds versus under-eyes versus Volume in cheeks versus Intense in lips?

Based on official FDA SSED trial tables:

Balance in nasolabial folds (P090016 ORIG): Evaluated at Week 12 (mean SRS 1.25 vs. collagen 1.51); 55.1% maintained >1-point improvement at Week 24; 95/106 elected OLEX retreatment, with a 37-week mean interval between injections during the extension.
Balance (+) in infraorbital hollows (P090016/S050): Primary Week-8 MI (ITT) 80.6% vs 1.9% untreated; observed Table 23 85.4% (111/130) at Week 8 and 81.4% (96/118) at Week 48.
Volume (+) in cheeks (P250020): 95.8% (137/143) live responders at Week 12; patient labeling establishes that results last up to 48 weeks in 74% of participants.
Intense (+) in lips (P250016): 91.1% (144/158) live MLFAS responders at Week 8; 48.7% (73/150) live fullness responders at Week 48; Week-48 GAIS 92.0% (138/150) investigator and 90.0% (135/150) subject.

Does Belotero last 18 months?

The "up to 18 months" claim is an upper-bound marketing envelope, not an average or median result. On the US HCP site it is footnoted with 20/22 (90.9%) Week-8 responders still responding at 72 weeks — the S050 infraorbital no-retreatment subset, not the original NLF Week-12 primary. In Belotero Volume patient labeling, cheek results lasted up to 48 weeks in 74% of participants, with only a select subset extending to 72 weeks. Most clinical patients should plan for maintenance inside the first year.

Is Belotero Intense FDA-approved for deep folds in the US, and when were Volume and Intense approved?

No. In the United States, Belotero Intense (+) Lidocaine was approved on July 9, 2026 under PMA P250016 specifically for lip augmentation in adults aged 21 and older. European marketing positions Intense for severe facial folds, but that indication is not FDA-approved in the US. Belotero Volume (+) Lidocaine was approved on May 19, 2026 under PMA P250020 for deep midface cheek augmentation.

Is Belotero Revive or Belotero Soft FDA-approved in the United States?

No. An exhaustive search of the FDA CDRH Premarket Approval database confirms that there are zero trade-name approvals for Belotero Soft, Belotero Revive, or Belotero Lips in the United States. These products are marketed in Europe, Latin America, and Asia under CE-mark regulations. Importing or injecting them in the US is use of an unapproved device, not "off-label" use of an FDA-approved syringe.

Can Belotero be dissolved if I do not like it?

Yes. Belotero is composed entirely of cross-linked hyaluronic acid and can be rapidly reversed using injected hyaluronidase. Because Belotero integrates smoothly into surrounding dermal tissue, it responds readily to hyaluronidase. For reversal timelines and expectations, see dissolving filler with hyaluronidase.

Sources

U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Belotero Balance Dermal Filler (PMA P090016). Notice of Approval November 14, 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090016B.pdf
U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Belotero Balance (+) Lidocaine for Infraorbital Hollows (PMA P090016/S050). Approved September 27, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090016S050B.pdf
U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Belotero Volume (+) Lidocaine for Midface Augmentation (PMA P250020). Approved May 19, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/P250020B.pdf
U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Belotero Intense (+) Lidocaine for Lip Augmentation (PMA P250016). Approved July 9, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/P250016B.pdf
U.S. Food and Drug Administration (FDA). Patient Labeling: Belotero Volume (+) Lidocaine (PMA P250020C). Approved May 19, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/P250020C.pdf
U.S. Food and Drug Administration (FDA). Patient Labeling: Belotero Intense (+) Lidocaine (PMA P250016C). Approved July 9, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/P250016C.pdf
U.S. Food and Drug Administration (FDA). CDRH Premarket Approval (PMA) Database: P250016 Decision Record (Belotero Intense (+) Lidocaine). July 9, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250016
U.S. Food and Drug Administration (FDA). CDRH Premarket Approval (PMA) Database: P250020 Decision Record (Belotero Volume (+) Lidocaine). May 19, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250020
U.S. Food and Drug Administration (FDA). Recently-Approved Devices: Belotero Balance (+) Lidocaine (P090016/S050). September 27, 2023. https://www.fda.gov/medical-devices/recently-approved-devices/belotero-balancer-p090016s050
Merz North America, Inc. Belotero Balance and Belotero Volume Healthcare Professional Information. Retrieved September 4, 2026. https://www.belotero.com/hcp
U.S. Food and Drug Administration (FDA). CDRH Premarket Approval (PMA) Database: P090016 Original Record (Belotero Balance). November 14, 2011. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090016
U.S. Food and Drug Administration (FDA). Physician Labeling: Belotero Balance Instructions for Use (PMA P090016C). Approved November 14, 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090016C.pdf

How Long Does Belotero Last? Product-by-Product PMA Duration, Not One 6-to-18-Month Number